Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Eni SpA (E) vs Humana Inc (HUM) Price & Performance

Humana IncTrade

Price performance (Past 24H)

Key statistics

Eni SpA vs Humana Inc — how do they compare? Eni SpA trades at $55.41 (market cap $79.81B), while Humana Inc trades at $444 (market cap $46.49B). The key difference: Eni SpA is the larger of the two by market cap, and Eni SpA pays the higher dividend (4.39%). Which is the better fit depends on your goals — on Pluang, investors hold Eni SpA for 53 Days and Humana Inc for 53 Days on average.

EHUM
Market Cap
$79.81B$46.49B
Volume
365,9122,567,704
Sector
EnergyHealth
52-Week High
$57.61$409.85
52-Week Low
$34.03$163.67
Typical Hold Time
53 Days53 Days
Enterprise Value
$104.34B$53.84B
Dividend Yield
4.39%0.91%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Eni SpA

Eni (E) trades at $53.96, down 1.08% on the day, amid a bearish technical signal and mixed earnings performance. Revenue has declined from $132.5B in 2022 to $82.15B in 2025, though net income margin improved to 5.97%. Recent news highlights strategic moves in humanoid robotics, LNG projects, and fuel discounts. The stock shows attractive valuation with a P/E of 12.87 and P/S of 0.85, while cash flow remains positive but net cash flow turned negative in 2026 projections.

The outlook is cautious; low valuations and dividend payments offer value, but revenue declines and earnings misses pose risks. Analyst consensus is mixed with 34.62% buy ratings. Key risks include energy price volatility and execution of new tech initiatives. Further upside depends on stabilizing revenue and meeting earnings expectations.

Humana Inc

Humana (HUM) trades at $396.51, down 1.92% on the day, with strong technical momentum showing bullish moving averages and key support at $391. The company demonstrates consistent revenue growth reaching $129.7B in 2025, though net margins have compressed to 0.88%. Recent quarterly earnings have exceeded expectations, with Q2 2026 EPS of $7.61 beating estimates of $7.27. Analyst sentiment remains positive with a $432.63 consensus price target representing 9% upside potential from current levels.

The investment case centers on Humana's dominant Medicare Advantage position and consistent revenue growth, though margin pressure and regulatory scrutiny present headwinds. With 43% of analysts maintaining buy ratings and institutional accumulation continuing, the stock offers exposure to healthcare demographics but requires monitoring of enrollment trends and cost management execution.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

E
63% Buy37% Sell
Avg holding period · 53 Days
HUM

No sentiment data available yet.

Top news

Latest headlines on both assets

About Eni SpA

Eni is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, the company produced 0.8 million barrels of liquids and 4.6 billion cubic feet of natural gas per day. At end-2021, Eni held reserves of 6.6 billion barrels of oil equivalent, 49% of which are liquids. The Italian government owns a 30.1% stake in the company. Eni is placing its renewable and low-carbon business in a separate entity, Plentitude

Read more on E →

About Humana Inc

Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.

Read more on HUM →